Please login to the form below

Not currently logged in
Email:
Password:

Scott Gottlieb

This page shows the latest Scott Gottlieb news and features for those working in and with pharma, biotech and healthcare.

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Former US Food and Drug Administration (FDA) commissioner Scott Gottlieb also said that rigorous confirmation is needed to further support the data, tweeting that “this is very encouraging but needs to

Latest news

More from news
Approximately 5 fully matching, plus 45 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    He replaced Scott Gottlieb, who was popular with industry but resigned from the post unexpectedly last year, as well as stand-in Ned Sharpless who has now returned to his post

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    In the early days of the Trump administration, then-FDA commissioner Scott Gottlieb made a point of clearing the way for even faster and more generic approvals, again with some apparent ... Based on those assumed savings, had all the FDA-approved

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The timing of the withdrawal was ironic given that, in the same month, FDA Commissioner Scott Gottlieb highlighted ‘TMB as a potential biomarker for enriching clinical trials testing immunotherapies’. ... Harmonisation. Gottlieb has since resigned,

  • Streamlining clinical trials – why better data use is key Streamlining clinical trials – why better data use is key

    Dr Scott Gottlieb’s brief, energetic tenure as US FDA Commissioner is likely to shape agency oversight of the pharmaceutical industry for years to come, particularly in relation to clinical development. ... To embrace innovations like blockchain, as

  • Cell and gene therapy Cell and gene therapy

    Interest in cell and gene therapies is undeniable. In January, US FDA Commissioner Scott Gottlieb outlined policies designed to accommodate an anticipated surge in cell and gene therapy submissions. ... Gottlieb highlighted manufacture as a challenge

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics